Pilot Study of Pegylated Interferon-Alfa 2b in Combination With PUVA [psoralens with ultraviolet light A] Therapy in Cutaneous T-Cell Lymphoma.

Trial Profile

Pilot Study of Pegylated Interferon-Alfa 2b in Combination With PUVA [psoralens with ultraviolet light A] Therapy in Cutaneous T-Cell Lymphoma.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 30 Nov 2013

At a glance

  • Drugs Peginterferon alfa-2b (Primary)
  • Indications Mycosis fungoides; Sezary syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 31 May 2013 Planned end date changed from 1 Jul 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.
    • 31 May 2012 Actual patient number 7 added as reported by ClinicalTrials.gov.
    • 31 May 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top